Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Minority Interest (2016)

Historic Minority Interest for Outlook Therapeutics (OTLK) over the last 2 years, with Q1 2016 value amounting to $17.4 million.

  • Outlook Therapeutics' Minority Interest changed N/A to $17.4 million in Q1 2016 from the same period last year, while for Mar 2016 it was $17.4 million, marking a year-over-year change of. This contributed to the annual value of $27.3 million for FY2015, which is N/A changed from last year.
  • Outlook Therapeutics' Minority Interest amounted to $17.4 million in Q1 2016.
  • Over the past 5 years, Outlook Therapeutics' Minority Interest peaked at $27.3 million during Q3 2015, and registered a low of $17.4 million during Q1 2016.